MindMed Announces Transitions to Management Team Post published:December 29, 2021 Post category:Press Release
Tryp Therapeutics Announces Advancement of Phase 2a Clinical Trial in Binge Eating Disorder Post published:December 23, 2021 Post category:Press Release
Numinus Wellness Commends Health Canada on Special Access Programme Amendments to Restore Potential Access to Psychedelic Medicines Post published:December 22, 2021 Post category:Press Release
Mydecine Signs LOI with Maya to Co-Develop a Novel Prescription Digital Therapeutic Platform Aiming to Further Increase Safety, Efficacy, and Accessibility of Psychedelic-Assisted Treatments Post published:December 22, 2021 Post category:Press Release
MindMed Provides Status Update on IND for Phase 2b Trial of LSD for the Treatment of Generalized Anxiety Disorder Post published:December 21, 2021 Post category:Press Release
Optimi Health Receives Dealers License Inspection and Introduces Quality Assurance Department Post published:December 21, 2021 Post category:Press Release
Lobe Sciences Announces Publication of PCT Patent Application for Its Combination Therapy for mTBI and PTSD Post published:December 21, 2021 Post category:Press Release
PharmaTher Provides Update on Product Pipeline and Expected Milestones for 2022 Post published:December 21, 2021 Post category:Press Release
Entheon Biomedical Announces Expanded Psychedelics Genetic Test Panel Post published:December 21, 2021 Post category:Press Release
HAVN Life Enters into Definitive Agreement to Acquire Spore Life Sciences Inc. Post published:December 20, 2021 Post category:Press Release